SEC Filing Details

SEC Filing Details

Document Details

Filing Date
Apr 25, 2022
Document Date
Apr 25, 2022
Form Description
Additional proxy soliciting materials - definitive
Filing Group
Proxy Filings
iTeos Therapeutics
Cancer Cells graphics

At iTeos we are pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics.

Our differentiated development approach is driven by biologic rationale and clinical need utilizing our IO candidates in intra-portfolio combinations and with programs of external collaborators.

Driven by a culture of scientific innovation, collaboration and excellence, together we discover and deliver breakthrough immunotherapies to improve and extend the lives of people with cancer.